FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Check this box to indicate that a Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* McKew John C.					2. I Ll	2. Issuer Name and Ticker or Trading Symbol LUMOS PHARMA, INC. [(LUMO)]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director						
4200 MARATHON BLVD SUITE 200					12	3. Date of Earliest Transaction (Month/Day/Year) 12/12/2024									Officer (give title Other (specify below) Chief Scientific Officer					
(Street) AUSTIN TX 78756				_ 4.1	If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)																	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction 2. Deemed 3. 4. Securities Acquired (A) or 5. Amount of 6. Ownership 7. Nature																				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					ay/Year) Execution		eemed tion Date h/Day/Yea	Transaction I Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)				Securitie Beneficia Owned F	5. Amount of Securities Beneficially Owned Following Reported		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	٧	Amount	(A) o (D)	r Prid	се	Transaction(s) (Instr. 3 and 4)						
Common Stock 12/1					2/2024					13,15			(1)	<u> </u>	0		D			
		٦	Fable II - I)						uired, Di , option						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution E if any (Month/Day	Date,	4. Transa Code (8)		of Deri Seci Acq (A) o Disp of (I	umber vative urities uired or oosed O) (Instr. and 5)	Expiration	Date Exercisable and Expiration Date (of Securities Underlying Derivative S (Instr. 3 and			ies g Secur	Derivat Securit (Instr. 5				10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Amou or Numb of Share	er						
Stock Option (Right to Buy)	\$2.84	12/12/2024			D			16,000	(2)	0.	3/31/2034	Common Stock	16,0	00	(2)	0		D		
Stock Option (Right to Buy)	\$3.52	12/12/2024			D			16,000	(2)		(2)	Common Stock	16,0	00	(2)	0		D		
Stock Option (Right to Buy)	\$2.45	12/12/2024			D			6,541	(2)	0	8/29/2028	Common Stock	6,54	11	(2)	0		D		
Stock Option (Right to Buy)	\$2.45	12/12/2024			D			9,583	(2)	0	1/18/2028	Common Stock	9,58	33	(2)	0		D		
Stock Option (Right to Buy)	\$4.82	12/12/2024			D			81,690	(3)	0	7/11/2026	Common Stock	81,6	90	(3)	0		D		
Stock Option (Right to Buy)	\$7.87	12/12/2024			D			65,000	(3)	0.	3/31/2030	Common Stock	65,0	00	(3)	0		D		
Stock Option (Right to Buy)	\$10.02	12/12/2024			D			14,000	(3)	0	1/31/2032	Common Stock	14,0	00	(3)	0		D		

Explanation of Responses:

\$17.35

12/12/2024

Stock Option

Buy)

(Right to

33,175

(3)

Common

Stock

33,175

0

D

01/31/2031

^{1.} Disposed of pursuant to that certain Agreement and Plan of Merger, dated October 22, 2024, by and between the Issuer, DPV Parent, Inc., DPV MergerSub, Inc. and Double Point Ventures LLC ("DPV") (the "Merger Agreement") in exchange for (i) \$4.25 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each restricted stock unit ("RSU") was cancelled and will receive the Cash Amount plus one CVR per RSU.

^{2.} This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash equal to the product of (x) the total number of shares underlying such option multiplied by (y) the excess of the Cash Amount over the applicable exercise price per share and (ii) one CVR for each share underlying such in-the-money option.

3. Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement.

Remarks:

/s/ Ryan Trytten, attorney-infact 12/13/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.